Adipotide, also known by its experimental code FTPP, is a synthetic peptidomimetic compound. It is designed to induce apoptosis (programmed cell death) in the endothelial cells of blood vessels supplying white adipose tissue (fat tissue). The underlying principle behind its development is that by disrupting the blood supply to fat cells, these cells will be deprived of oxygen and nutrients, leading to their reduction. Adipotide was initially developed in preclinical research settings as a potential agent for treating obesity and related metabolic conditions. It is not currently approved for human use by regulatory bodies like the FDA or EMA and remains an investigational compound. Its structure is based on a pro-apoptotic peptide linked to a homing sequence that specifically targets a receptor found predominantly on the surface of blood vessels in white fat, but not in other tissues or organs, aiming for a targeted effect.
Deep dive
Tap a section to expand.
Known interactions
Category rule: peptide × hormone
Note
Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.
Track bloodwork with a provider; don't assume combinations are neutral.
Frequently asked
Sources referenced
["PubMed Central","NIH ODS (Office of Dietary Supplements)","PubChem","DrugBank","Science Translational Medicine"]
Stackwise compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician.
Related compounds
Others in the peptide category or studied for the same goals.